Atrion Reports Fourth Quarter and Full Year 2021 Results

Rhea-AI Summary

Atrion Corporation (NASDAQ: ATRI) reported its Q4 2021 results, showing revenues of $40.3 million, up 25% from Q4 2020. Net income rose to $8.1 million, with diluted EPS at $4.50, a $0.48 increase year-over-year. For the full year 2021, revenues reached $165.0 million, a 12% increase, and net income was $33.1 million, reflecting a 3% rise. Challenges included higher labor costs and supply chain issues, impacting operational efficiency. CEO David Battat anticipates double-digit growth in 2022, driven by their MPS 3 technology and continued R&D investments.

Positive

• Q4 2021 revenues increased to $40.3 million, a 25% rise from Q4 2020.
• Net income for Q4 2021 was $8.1 million, up from $7.4 million in Q4 2020.
• Full year 2021 revenues rose to $165.0 million, a 12% increase from 2020.
• Diluted EPS for full year 2021 was $18.18, compared to $17.44 in 2020.
• CEO forecasts double-digit revenue and operating income growth for 2022.

Negative

• Operating income for full year 2021 was flat due to higher labor costs and supply chain disruptions.
• Increased operational inefficiencies due to social distancing measures during the pandemic.

ALLEN, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the fourth quarter ended December 31, 2021 and the full year 2021.

Revenues for the fourth quarter of 2021 totaled $40.3 million compared to $32.2 million for the same period in 2020. Net income for the fourth quarter of 2021 totaled $8.1 million, an increase of $0.7 million compared to the same period in 2020. Fourth quarter 2021 diluted earnings per share were $4.50 compared to $4.02 for the fourth quarter of 2020. For the full year 2021 compared to the full year 2020, revenues increased to $165.0 million from $147.6 million, net income was $33.1 million versus $32.1 million, and diluted earnings per share were $18.18 compared to $17.44.

Commenting on the results for the fourth quarter of 2021 compared to the prior year period, David Battat, President and CEO, stated, “I am pleased to report that despite the impact of the pandemic, revenues were up by 25% and operating income was up by 24% while net income was up by a smaller 10% due, in part, to weaker performance in our investment portfolio in the quarter.” Mr. Battat added, “Although the increase in revenues came from many products, the largest single contributor was our state-of-the-art myocardial protection system console, or MPS 3, and associated disposables. These increases in revenues and operating income further validate our focus on adding new technologies and new customers, as well as continuing to invest in our people and the latest automation.

Mr. Battat continued, “For the full year 2021 compared to the full year 2020, revenues were up by 12% while operating income was flat, impacted by higher labor costs, supply chain disruptions, and inefficiencies in the layouts of our work cells to allow for social distancing and other employee safety measures necessitated by the pandemic. Net income for the year was up by 3%, favorably impacted by lower tax rates.”

Addressing expectations for 2022, Mr. Battat stated, “Barring major events such as a resurgence of COVID-19 or further supply chain disruptions, we expect double-digit increases in revenues and operating income." Mr. Battat concluded, "I have never been more excited by the breadth and depth of our R&D pipeline, including work being done to expand the applications for our MPS3 platform technology."

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, Atrion's expectations regarding increases in revenues and operating income in 2022. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.    

Contact:	Jeffery Strickland
	Vice President and Chief Financial Officer
	(972) 390-9800

ATRION CORPORATION UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data)
	Three Months Ended December 31,								Twelve Months Ended December 31,
		2021				2020				2021				2020
Revenues	$	40,293			$	32,244			$	165,009			$	147,591
Cost of goods sold		22,917				18,315				95,637				81,428
Gross profit		17,376				13,929				69,372				66,163
Operating expenses		9,538				7,604				33,330				30,495
Operating income		7,838				6,325				36,042				35,668
Interest and dividend income		163				283				843				1,444
Other investment income (loss)		625				1,350				1,477				1,355
Other income		--				--				67				--
Income before income taxes		8,626				7,958				38,429				38,467
Income tax provision		(499	)			(588	)			(5,374	)			(6,352	)
Net income	$	8,127			$	7,370			$	33,055			$	32,115
Income per basic share	$	4.51			$	4.03			$	18.22			$	17.49
Weighted average basic shares
outstanding		1,801				1,828				1,814				1,836
Income per diluted share	$	4.50			$	4.02			$	18.18			$	17.44
Weighted average diluted shares
outstanding		1,806				1,832				1,818				1,841

        

ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands)
	Dec. 31,			Dec. 31,
ASSETS	2021			2020
	(Unaudited)
Current assets:
Cash and cash equivalents	$	32,264		$	22,450
Short-term investments		29,059			19,258
Total cash and short-term investments		61,323			41,708
Accounts receivable		21,023			16,445
Inventories		50,778			50,298
Prepaid expenses and other		3,447			3,868
Total current assets		136,571			112,319
Long-term investments		19,423			46,207
Property, plant and equipment, net		97,972			94,935
Other assets		13,298			13,429
	$	267,264		$	266,890
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities		13,346			13,636
Line of credit		--			--
Other non-current liabilities		9,622			12,812
Stockholders’ equity		244,296			240,442
	$	267,264		$	266,890

FAQ

What were Atrion Corporation's Q4 2021 revenue results?

Atrion Corporation reported Q4 2021 revenues of $40.3 million, a 25% increase from Q4 2020.

What was the net income for Atrion for the full year 2021?

Atrion's net income for the full year 2021 was $33.1 million, an increase of 3% from the previous year.

How does Atrion Corporation's diluted EPS for 2021 compare to 2020?

The diluted earnings per share for Atrion in 2021 was $18.18, compared to $17.44 in 2020.

What challenges did Atrion face in 2021?

Atrion faced challenges such as higher labor costs and supply chain disruptions, impacting operational efficiency.

What growth does Atrion anticipate for 2022?

Atrion expects double-digit increases in revenues and operating income for 2022, barring major disruptions.